HUE030737T2 - Modafinil kokainfüggõk kezelésében történõ alkalmazásra - Google Patents

Modafinil kokainfüggõk kezelésében történõ alkalmazásra Download PDF

Info

Publication number
HUE030737T2
HUE030737T2 HUE13715263A HUE13715263A HUE030737T2 HU E030737 T2 HUE030737 T2 HU E030737T2 HU E13715263 A HUE13715263 A HU E13715263A HU E13715263 A HUE13715263 A HU E13715263A HU E030737 T2 HUE030737 T2 HU E030737T2
Authority
HU
Hungary
Prior art keywords
cocaine
treatment
modafinil
composition
dissolution
Prior art date
Application number
HUE13715263A
Other languages
English (en)
Inventor
Pascal Suplie
Philippe Vivet
Original Assignee
Debregeas Et Associes Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debregeas Et Associes Pharma filed Critical Debregeas Et Associes Pharma
Publication of HUE030737T2 publication Critical patent/HUE030737T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Claims (5)

  1. Szabadalma Igénypontok 1. S-niodaítml--alapü gyógyszerészed készítmény kokaminggók helyettesítő kezelésében tórtéuó alkalmazásra, azzal jellemezve, hogy az S~modafimli szuperkritikus folyadék technológiával kapjuk, az S-atodáfutil egy Inert hordozóban létrehozott granulátumok léiül el én abszorbeált,
  2. 2. Készítmény alkalmazásra az 1, igénypont szerint, azzal jellemezve, hogy a folyadék a 40;.
  3. 3. K-észltmény alkalmazásra az 1, vagy 2, igénypont szerint, azzal jellemezve, hogy a hordozó vízmentes laktöz.
  4. 4. Készítmény alkalmazásra az 1... vagy 2. igénypont szerint, azzal jellemezve, begy a hordozd marmit,
  5. 5. Készítmény a lka !tn ázásra az 1 -4 igénypontok bártnelyike szerint, azzal jellemezve, hogy a készítmény tabletta formájú, 4 Kiszitmény alkalmazásra az 5, igénypont szerint, azzal jellemezve, hogy a tabletta 25-200 mg S-modaiímit tartalmaz- ?. Készítmény alkalmazásra a 6, igénypont szerint, azzal jellemezve, hogy a tabletta 50400 mg S-modafiniit tartalmaz.
HUE13715263A 2012-02-28 2013-02-25 Modafinil kokainfüggõk kezelésében történõ alkalmazásra HUE030737T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1200581A FR2987267B1 (fr) 2012-02-28 2012-02-28 Application du modafinil dans le traitement de substitution des cacainomanes

Publications (1)

Publication Number Publication Date
HUE030737T2 true HUE030737T2 (hu) 2017-05-29

Family

ID=48083447

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13715263A HUE030737T2 (hu) 2012-02-28 2013-02-25 Modafinil kokainfüggõk kezelésében történõ alkalmazásra

Country Status (33)

Country Link
US (1) US20150073055A1 (hu)
EP (1) EP2819655B1 (hu)
JP (1) JP6163169B2 (hu)
KR (1) KR101897855B1 (hu)
CN (1) CN104159575B (hu)
AR (1) AR090169A1 (hu)
AU (1) AU2013224831B2 (hu)
BR (1) BR112014020626A2 (hu)
CA (1) CA2863159C (hu)
CL (1) CL2014002203A1 (hu)
CY (1) CY1118166T1 (hu)
DK (1) DK2819655T3 (hu)
EA (1) EA025692B1 (hu)
ES (1) ES2593276T3 (hu)
FR (1) FR2987267B1 (hu)
HR (1) HRP20161165T1 (hu)
HU (1) HUE030737T2 (hu)
IL (1) IL234009B (hu)
IN (1) IN2014DN07831A (hu)
LT (1) LT2819655T (hu)
MX (1) MX348222B (hu)
NZ (1) NZ628009A (hu)
PH (1) PH12014501837A1 (hu)
PL (1) PL2819655T3 (hu)
PT (1) PT2819655T (hu)
RS (1) RS55238B1 (hu)
SG (1) SG11201405316WA (hu)
SI (1) SI2819655T1 (hu)
SM (1) SMT201600363B (hu)
TW (1) TWI626042B (hu)
UA (1) UA113301C2 (hu)
WO (1) WO2013128088A1 (hu)
ZA (1) ZA201405910B (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105055404B (zh) * 2015-08-19 2017-07-18 四川大学 Hmgcs2抑制剂在制备治疗可卡因成瘾的药物中的用途
CN105055412B (zh) * 2015-08-20 2018-06-19 四川大学 Nampt抑制剂在制备治疗可卡因成瘾的药物中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
FR2771004B1 (fr) 1997-11-19 2000-02-18 Inst Curie Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse
US20010034373A1 (en) 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
DE60137069D1 (de) * 2000-10-11 2009-01-29 Cephalon Inc Arzneizusammensetzungen enthaltend modafinilverbindungen
US20040006532A1 (en) 2001-03-20 2004-01-08 David Lawrence Network access risk management
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
US7093476B2 (en) 2004-09-15 2006-08-22 Ut-Battelle, Llc Method for fabricating thin californium-containing radioactive source wires
WO2007013962A2 (en) * 2005-07-21 2007-02-01 Neurohealing Pharmaceuticals, Inc. Rapid onset and short term modafinil compositions and methods of use thereof
AU2007272501A1 (en) * 2006-07-12 2008-01-17 Elan Pharma International Limited Nanoparticulate formulations of modafinil
EP1980240A1 (en) * 2007-04-11 2008-10-15 Cephalon France Lyophilized pharmaceutical compositions and methods of making and using same
US8173169B2 (en) * 2007-07-11 2012-05-08 Hikma Pharmaceuticals Formulation and process for the preparation of modafinil

Also Published As

Publication number Publication date
IN2014DN07831A (hu) 2015-04-24
KR20140135162A (ko) 2014-11-25
PH12014501837A1 (en) 2014-11-10
BR112014020626A2 (pt) 2017-06-27
EP2819655A1 (fr) 2015-01-07
EA201400960A1 (ru) 2014-12-30
CA2863159A1 (fr) 2013-09-06
HRP20161165T1 (hr) 2016-11-04
JP2015508805A (ja) 2015-03-23
WO2013128088A1 (fr) 2013-09-06
UA113301C2 (xx) 2017-01-10
EA025692B1 (ru) 2017-01-30
EP2819655B1 (fr) 2016-07-27
CN104159575A (zh) 2014-11-19
TWI626042B (zh) 2018-06-11
LT2819655T (lt) 2016-10-25
SI2819655T1 (sl) 2016-11-30
DK2819655T3 (en) 2016-11-28
FR2987267A1 (fr) 2013-08-30
FR2987267B1 (fr) 2015-01-16
AU2013224831B2 (en) 2017-05-11
SMT201600363B (it) 2016-11-10
CA2863159C (fr) 2018-06-12
US20150073055A1 (en) 2015-03-12
PL2819655T3 (pl) 2017-01-31
ZA201405910B (en) 2017-04-26
RS55238B1 (sr) 2017-02-28
CL2014002203A1 (es) 2015-04-10
IL234009B (en) 2018-01-31
SG11201405316WA (en) 2014-11-27
MX2014010237A (es) 2015-07-17
MX348222B (es) 2017-06-05
WO2013128088A8 (fr) 2014-09-12
NZ628009A (en) 2015-07-31
ES2593276T3 (es) 2016-12-07
KR101897855B1 (ko) 2018-09-12
CN104159575B (zh) 2018-09-04
TW201340964A (zh) 2013-10-16
PT2819655T (pt) 2016-10-14
JP6163169B2 (ja) 2017-07-12
IL234009A0 (en) 2014-09-30
AR090169A1 (es) 2014-10-22
CY1118166T1 (el) 2017-06-28
AU2013224831A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
JP6966584B2 (ja) ドラベ症候群の処置における使用のためのフェンフルラミン
Kang et al. Comparison of short‐versus long‐term ketogenic diet for intractable infantile spasms
ES2380060T3 (es) Composiciones farmacéuticas de un esteroide neuroactivo y usos de las mismas
US20170319556A1 (en) Methods of treating developmental disorders using gaboxadol
Wilder et al. Gastrointestinal tolerance of divalproex sodium
WO1995007103A1 (en) Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
EP1032376A1 (fr) Utilisation de derives de benzhydryl sulfinyle pour traiter la somnolence d'origine medicamenteuse
Xie et al. In vitro and in vivo evaluations of PLGA microspheres containing nalmefene
Naeem et al. Development and evaluation of controlled-release bilayer tablets containing microencapsulated tramadol and acetaminophen
US20200383924A1 (en) Modified release formulations and uses thereof
EP1343495A2 (en) Methods of treating anxiety disorders
WO2021222342A1 (en) Methods of use of t-type calcium channel modulators
CN104706604A (zh) 一种吡仑帕奈冻干口崩片及其制备方法
HUE030737T2 (hu) Modafinil kokainfüggõk kezelésében történõ alkalmazásra
Wu et al. Effects of avitinib on the pharmacokinetics of osimertinib in vitro and in vivo in rats
CN111818913B (zh) 含有拉科酰胺的药剂学缓释性组合物
Benítez-Rosario et al. Methadone-induced respiratory depression after discontinuing carbamazepine administration
KR20130103342A (ko) 신경장애성 동통의 치료제 또는 예방제
Aamir et al. Production and stability evaluation of modified-release microparticles for the delivery of drug combinations
Nicholson et al. Development of oral extended release formulations of 6‐hydroxybuspirone
US20140142113A1 (en) Method of treating inflammatory diseases using adenosine 2b receptor antagonists
WO2023247665A1 (en) Solid dispersions of psilocybin
CN101420947A (zh) 用于非恢复性睡眠的α-2-δ配体
JP2022087834A (ja) 放出調節製剤およびその使用
US20170246194A1 (en) Acetaminophen-Containing Analgesic Formulations With Reduced Hepatotoxicity